Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis

Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy

(2012) Ching-Wei D. Tzeng et al.   ANNALS OF SURGICAL ONCOLOGY

Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial

(2011) William F. Regine et al.   ANNALS OF SURGICAL ONCOLOGY

Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer

(2011) Chang Moo Kang et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment

(2011) Shinichiro Takahashi et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy

(2010) Douglas B. Evans et al.   ANNALS OF SURGICAL ONCOLOGY

Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?

(2010) Matthew H. G. Katz et al.   ANNALS OF SURGICAL ONCOLOGY

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

(2009) Mark P. Callery et al.   ANNALS OF SURGICAL ONCOLOGY

Determining Pattern of Recurrence Following Pancreaticoduodenectomy and Adjuvant 5-Flurouracil-Based Chemoradiation Therapy: Effect of Number of Metastatic Lymph Nodes and Lymph Node Ratio

(2008) Bolanle Asiyanbola et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease

(2008) Matthew H.G. Katz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS